Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse

International Immunopharmacology

Volumn 11, Issue 7, 2011, Pages 862-872

  Kim, Seung Wook ^a   Kim, Jang Seong ^a   Papadopoulos, John ^a   Choi, Hyun Jin ^a   He, Junqin ^a   Maya, Marva ^a   Langley, Robert R ^a   Fan, Dominic ^a   Fidler, Isaiah J ^a   Kim, Sun Jin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone metastasis; Macrophages; Prostate cancer

Indexed keywords

CLODRONIC ACID; INTERLEUKIN 6; LIPOSOME; PHOSPHATE BUFFERED SALINE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; GENE SILENCING; GENETIC TRANSFECTION; LENTIVIRINAE; LYMPH NODE METASTASIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR NECROSIS; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

EID: 79958071589     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.01.004     Document Type: Article

References (57)

1. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61. (Pubitemid 29244499)
2. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993;13:443-9. (Pubitemid 23196786)
3. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res 1990;50:6130-8. (Pubitemid 20323663)
4. Fidler IJ. Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl Cancer Inst 1995;87:1588-92.
5. Talmadge JE, Fidler IJ. AACR Centennial Series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70(14):5649-69.
6. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30:39-50. (Pubitemid 36712858)
7. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006;98:783-93. (Pubitemid 43983302)
8. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-11.
9. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78. (Pubitemid 23289250)
10. Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003;91:545-53.
11. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004;60:178-86. (Pubitemid 38971829)
12. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, et al. Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear docetaxel antitumor activity. Clin Cancer Res 2006;12:5578-6686.
13. Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-12. (Pubitemid 28101778)
14. Goswami S, Gupta A, Sharma SK. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiform cell line U87MG. J Neurochem 1998;71:1837-45. (Pubitemid 28491538)
15. Foti E, Ferrandina G, Martucci R, Romanini ME, Benedetti PP, Testa U, et al. IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology 1999;57:211-5.
16. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7. (Pubitemid 29422316)
17. Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7786-8.
18. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinoma and benign prostate hyperplasia. J Urol 1994;151:1396-9. (Pubitemid 24121965)
19. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch Jr G, Klocker H, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191:239-44. (Pubitemid 30441246)
20. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33. (Pubitemid 29446967)
21. Stark JR, LI H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009;124:2683-9.
22. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approach? World J Urol 2007;25:477-89.
23. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr-Relat Cancer 2009;16:155-69.
24. Xie S, Lin HK, Ni J, Yang L, Wang L, di Sant'Agnese PA, et al. Regulation of interleukin-6 mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate 2004;60:61-7. (Pubitemid 38669230)
25. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer in mediated by Mcl-1. Oncogene 2007;26:2822-32. (Pubitemid 46701444)
26. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenograft in nude mice. Prostate 2001;48:47-53.
27. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004;40:1066-72.
28. Steiner H, Canarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, et al. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 2006;66:1744-52. (Pubitemid 44893900)
29. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-22. (Pubitemid 44922352)
30. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6. (Pubitemid 43121975)
31. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
32. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2004;351:2817-26.
33. Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extramural macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009;11:177-86.
34. Mizutani K, Sud S, McGregor NA, Martinivski G, Rice BT, Craig MJ, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009;11:1235-42.
35. Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 1990;50:6683-8. (Pubitemid 20348800)
36. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36. (Pubitemid 126447459)
37. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ. Tissue-specific microvascular endothelial cell lines from H-2Kb-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003;63:2972-6.
38. Baeza-Raja B, Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 2004;15:2013-26. (Pubitemid 38401847)
39. Robinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003;33:401-6. (Pubitemid 36278858)
40. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat 3 signaling pathway. Prostate 2000;42:239-42. (Pubitemid 30080423)
41. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenograft in mice by the process of neuroendocrine differentiation. Int J Cancer 2004;111:508-13. (Pubitemid 39045316)
42. Nakao S, Kuwano T, Tsusumi-Miyahara C, Ueda S, Kimura YN, Hamano S, et al. Infiltration of COX-2 expressing macrophages is a prerequisite for IL-1 betainduced neovascularization and tumor growth. J Clin Invest 2005;115:2979-91. (Pubitemid 41567564)
43. Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J Immunol Meth 1989;124:1-6.
44. Bianco C, Griffin FM, Silverstein SC. Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J Exp Med 1975;141:1278-90.
45. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, et al. Simultaneous blockade of platelet-derived growth factor receptor and epidermal growth factor receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64:4201-8. (Pubitemid 38802424)
46. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted byhuman ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005;65:10794-800. (Pubitemid 41713347)
47. Hirsch S, Austyn JM, Gordon S. Expression of the macrophage-specific antigen F4/80 during differentiation of mouse bone marrow cells in culture. J Exp Med 1981;154:713-25. (Pubitemid 11060783)
48. Chun L, Yoon J, Song Y, Huie P, Regula D, Goodman S. The characterization of macrophages and osteoclasts in tissues harvested fromrevised total hip prostheses. J Biomed Mater Res 1999;48:899-903.
49. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65:3707-15. (Pubitemid 40616348)
50. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclasts function. Calcif Tissue Int 1982;34:285-90. (Pubitemid 12060442)
51. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-6. (Pubitemid 38961893)
52. Horowitz SM, Purdon MA. Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Calcif Tissue Int 1995;57:301-5.
53. Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene causes hypercalcemia as well as cachexia, leukocytosis, and thrombocytosis in tumor-bearing nude mice. Endocrinology 1991;128:2657-9.
54. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNF-α potently activates osteoclasts through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002;143:1108-18. (Pubitemid 34164059)
55. Steven L, Teitelbaum M, Tondravi M, Ross FP. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukoc Biol 1997;61:381-8. (Pubitemid 27219830)
56. Quinn JM, McGee JO, Athanasou NA. Human tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells. J Pathol 1998;184:31-6. (Pubitemid 28086150)
57. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.